Patients diagnosed with MS according to the NCEP-ATPIII criteria who were receiving standard of care were assigned to either curcuminoids ( C@ complex ( ) ; @ mg/day ; n = @ ) or placebo ( n = @ ; matched with drug capsules in shape and color ) for @ weeks .